Higher SIRT1 levels had been associated with resistance to the kinase inhibitor sorafenib and to multiple other antitumor agents including cisplatin, oxaliplatin, 5-fluorouracil, doxorubicin, and pirarubicin in a variety of tumours [32,79,97]. Here, SIRT1 is linked to neoplasm.